Cargando…
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine pati...
Autores principales: | Bramhall, S R, Hallissey, M T, Whiting, J, Scholefield, J, Tierney, G, Stuart, R C, Hawkins, R E, McCulloch, P, Maughan, T, Brown, P D, Baillet, M, Fielding, J W L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375430/ https://www.ncbi.nlm.nih.gov/pubmed/12085177 http://dx.doi.org/10.1038/sj.bjc.6600310 |
Ejemplares similares
-
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
por: Bramhall, S R, et al.
Publicado: (2002) -
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
por: Primrose, J N, et al.
Publicado: (1999) -
A phase II trial of marimastat in advanced pancreatic cancer
por: Evans, J D, et al.
Publicado: (2001) -
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA
por: Watson, S A, et al.
Publicado: (1999) -
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
por: Jones, P H, et al.
Publicado: (2004)